The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InRevelation Biosciences Inc. (NASDAQ: REVB) has released additional clinical data from its PRIME study evaluating the drug candidate Gemini. The latest findings demonstrate Gemini's ability to normalize cellular inflammation and restore immunocompetence in patients with stage 3 and 4 chronic kidney disease (CKD). Presented at the AKI & CRRT 2026 conference, the data showed that a single dose could sustain immune restoration for up to 7 days. The company aims to highlight Gemini's therapeutic potential in treating hyperinflammatory states and addressing immunoparalysis. This announcement marks a significant milestone for the clinical-stage biotech firm as it advances its specialized pipeline. Market analysts view these results as a bullish catalyst for REVB shares, reflecting progress in addressing critical unmet medical needs in nephrology.